SEARCH

SEARCH BY CITATION

References

  • 1
    Fielding JF & Cooke WT. Pregnancy and Crohn’s disease. Br Med J 1970; 2: 76 7.
  • 2
    McEwan HP. Ulcerative colitis in pregnancy. Proc R Soc Med 1972; 65: 279 81.
  • 3
    Nielsen OH, Andreasson B, Bondensen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735 42.
  • 4
    Khosla R, Willoughby CP, Jewell DP. Crohn’s disease and pregnancy. Gut 1984; 25: 52 6.
  • 5
    Baiocco PJ & Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984; 6: 211 16.
  • 6
    Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990; 99: 987 94.
  • 7
    Järnerot G. Management of IBD in pregnancy. Res Clin Forum 1993; 15: 137 43.
  • 8
    Nielsen OH, Andreasson B, Bondensen S, Jacobsen O. Pregnancy in Crohn’s disease. Scand J Gastroenterol 1984; 19: 724 32.
  • 9
    Carson SA & Simpson JL. Spontaneous abortion. In: Eden RD, Boehm FH, eds. Assessment & Care of the Fetus. East-Norwalk, Connecticut: International Edition, 1990: 559–74.
  • 10
    Briard ML, Feingold J, Bonaiti-Pellie C, Lapeyre F, Frezal J, Varangot J. Fréquence des malformations à la naissance. Etude d’une maternité parisienne. Arch Franç Péd 1975; 32: 123 38.
  • 11
    Fréquence des malformations à la naissance. Etude d’une maternité parisienne pendant 5 ans. J Gyn Obst Biol Repr 1982; 11: 215 26.
  • 12
    Bortoli A, Tartarella M, Prada A, et al. Inflammatory bowel disease and pregnancy. Gastroenterology 1997; 112: A940(Abstract).
  • 13
    Saarokoski S & Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to fetus. Am J Obstet Gynecol 1973; 115: 1100 6.
  • 14
    Järnerot G, Into-Malmberg MB, Esbjorner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16: 693 7.
  • 15
    Christensen LA, Rasmussen SN, Hansen S, Bondesen S, Hvidberg EF. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand 1987; 66: 433 5.
  • 16
    Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80: 72 6.
  • 17
    Lewis JH & Weingold AB. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 1985; 80: 912 13.
  • 18
    Alstead EM, Ritchies JK, Lennard-Jones JE, Farthing MJG, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443 6.
  • 19
    Erkman J & Blythe JG. Azathioprine therapy complicated by pregnancy. Obstet Gynecol 1972; 40: 708 10.
  • 20
    Meehan RT & Dorsey JK. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol 1987; 14: 252 9.
  • 21
    Registration Committee of the European Dialysis and Transplant Association. Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynecol 1980; 87: 839 45.
  • 22
    Kozlowski RD, Steinbrunner JV, McKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 1121 5.
  • 23
    Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a metanalysis. Am J Obstet Gynecol 1995; 172: 525 9.
  • 24
    Craxi A & Pagliarello F. Possible embryotoxicity of sulphasalazine. Arch Intern Med 1980; 140: 1674.
  • 25
    Newman NM & Correy JF. Possible teratogenicity of sulphasalazine. Med J Aust 1983; 1: 528 9.
  • 26
    Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 1988; 318: 1128 9.
  • 27
    Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993; 105: 1057 60.
  • 28
    Trallori G, D’albasio G, Bardazzi G, et al. 5-aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 1994; 26: 75 8.
  • 29
    Jonville Bera AP, Soyez C, Fignon A, Moraine C, Berger C, Autret E. Pentasa® (mesalazine) et grossesse. Therapie 1994; 49: 443 5.
  • 30
    Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994; 344: 620 1.
  • 31
    Diav-Citrin O, Park Y, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23 8.
  • 32
    Marteau P & Devaux C. Mesalazine during pregnancy. Lancet 1994; 344: 1708 9.
  • 33
    Danpure CJ & Purdue PE. Primary hyperoxaluria. In: Scriver CR, Beaudet AL, Sly VS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th edn. New York: McGraw-Hill Inc., 1993: 2385–424.
  • 34
    Moore BD. Pediatric cataracts—Diagnosis and treatment. Optom Vis Sci 1994; 71: 168 73.
  • 35
    Edmonds LD & James LM. Temporal trends in the incidence of malformation in the United States, selected years 1970–71, 1982–83. Morbidity & Mortality Weekly Report: Centre of Disease Control 1985; 34: 1SS 3SS.